Malaga

• TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended
  2023-505894-33-00 4 2020-11-25 Lung Cancer, Non-Small Cell
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro … Ended
  2023-510107-22-00 5 2020-10-27 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• Study to evaluate the efficacy and safety of cetuximab plus irinotecan compared to investigator's choice therapy in patients with metastatic … Ended
  2024-518728-59-00 4 2020-10-23 metastatic colorectal cancer
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• “A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastati … Ended
  2023-509387-24-00 4 2020-09-02 Metastatic hormone–naïve prostate cancer (mHNPC)
• Clinical trial to assess the efficacy and safety of a vaccine for dust mite allergy Ended
  2024-514090-21-00 5 2020-08-05 Aetiological treatment of moderate - severe intermittent or persistent
• Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended
  2022-500820-31-00 4 2020-07-16 Recurrent or metastatic squamous cell carcinoma of the head and neck
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission … Ended
  2023-507221-42-00 5 2020-06-03 Acute Myeloid Leukemia in First Remission
• A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an … Ended
  2022-502482-17-00 5 2020-05-19 Non-small cell lung cancer (NSCLC)
• Extension study to evaluate the long-term outcomes of subjects in study 20090 Ended
  2023-504207-89-00 5 2020-03-27 Retinopathy of prematurity
• A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi … Ended
  2023-507276-53-00 4 2020-03-23 Myelofibrosis
• Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in … Ended
  2023-508993-27-00 4 2020-01-17 Chronic myelogenous leukemia
• An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev … Ended
  2022-502361-15-00 5 2019-12-12 Moderate-to-Severe Plaque Psoriasis
• Study to evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant Ended
  2023-508135-30-00 4 2019-12-09 Breast cancer patients including those with locally advanced (unresect
• A study to learn if Bimekizumab is safe and works over a long period in adults with Active Psoriatic Arthritis Ended
  2023-506528-95-00 5 2019-11-21 Psoriatic Arthritis
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace … Ended
  2022-503050-39-00 5 2019-11-12 Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) w
• Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended
  2023-506657-38-00 5 2019-10-02 Biliary Tract Carcinoma
• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma
• Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended
  2023-503956-29-00 5 2019-08-26 Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient M
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• The Late Presenter Treatment Optimisation Study (LAPTOP) Ended
  2023-505167-36-00 5 2019-08-05 Patients who present late on during their acquisition of the HIV-1 (Hu

Showing 985–1,008 of 1,048 trials